Cytel unlocks innovative clinical development expertise for APAC biopharma sector
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
Two main objectives are: Accelerate novel technologies and products for global markets; and Connect academia and industry, creating synergy for faster advancement of the Bioprotection sector
India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency
Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
Subscribe To Our Newsletter & Stay Updated